| Name | Title | Contact Details |
|---|
BodyTel is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Magpie Healthcare is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clear skin can be life-changing, but it`s not easy to see a dermatologist. At Curology, we provide prescription medications custom-formulated for each patient`s skin and shipped directly to their door. We tailor the entire Curology experience specifically for patients with acne and anti-aging concerns, allowing us to provide incredibly personalized, effective and affordable care at scale. We`ve assembled a committed team of dermatology providers and created a secure online platform, bringing professional acne care and prescription treatment to tens of thousands of people who wouldn`t otherwise be able to access or afford it. Curology helps people see tremendous, long-term improvements previously accessible only to a small percentage of the population. Our formulas are already on tens of thousands of sinks across the US. Our technology enables 1:1 chats with real dermatology providers and lets users to share their journeys with an engaged and growing community. Members can upload photos and track their progress over SMS, as well as browse and post digital postcards to share victories and encourage others. Curology is headquartered in the beautiful Hayes Valley neighborhood of San Francisco.
NDSC`s solutions are widely adopted and in use across the entire healthcare provider market in all 50 states and Europe. Organizations ranging from large, multi-state, integrated delivery networks to standalone ambulatory care settings, caregivers trust NDSC CareSelect™ platform to manage and track the actionable delivery of thousands of evidence-based guidelines.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.